Literature DB >> 7473242

Decreased calcium currents in motor nerve terminals of mice with Lambert-Eaton myasthenic syndrome.

D O Smith1, M W Conklin, P J Jensen, W D Atchison.   

Abstract

1. The effects of immunoglobulin G (IgG) from patients with Lambert-Eaton myasthenic syndrome on Ca2+ currents in mammalian motor nerve terminals are unknown. Therefore, we recorded these currents in phrenic nerves of mice injected with serum from either LEMS patients, myasthenia gravis patients, or healthy control individuals. 2. In control preparations, the endplate currents induced by repetitive stimulation at > or = 20 Hz were depressed as expected. However, in the LEMS animals quantal content decreased and either depression did not occur or synaptic facilitation occurred. 3. Ca2+ currents were smaller in LEMS animals. At 0.5 Hz stimulation frequency, normalized Ca2+ currents in LEMS animals were 57 +/- 14% of those in control. At higher frequencies, Ca2+ currents become smaller in control but not in LEMS animals. 4. Ca2+ currents in controls were unaffected by addition of nifedipine but were reduced by 37% upon addition of omega-conotoxin GVIA. In LEMS animals, however, the currents were depressed by 43% by nifedipine but were unaffected by omega-conotoxin GVIA. Thus, LEMS is associated with reduced Ca2+ currents and a shift to dihydropyridine sensitivity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7473242      PMCID: PMC1156603          DOI: 10.1113/jphysiol.1995.sp020865

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  30 in total

1.  Quantal components of end-plate potentials in the myasthenic syndrome.

Authors:  E H Lambert; D Elmqvist
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

2.  Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma.

Authors:  D Elmqvist; E H Lambert
Journal:  Mayo Clin Proc       Date:  1968-10       Impact factor: 7.616

3.  A quantitative study of end-plate potentials in isolated human muscle.

Authors:  D Elmqvist; D M Quastel
Journal:  J Physiol       Date:  1965-06       Impact factor: 5.182

4.  On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates.

Authors:  S G Cull-Candy; R Miledi; A Trautmann; O D Uchitel
Journal:  J Physiol       Date:  1980-02       Impact factor: 5.182

Review 5.  Inactivation of Ca channels.

Authors:  R Eckert; J E Chad
Journal:  Prog Biophys Mol Biol       Date:  1984       Impact factor: 3.667

6.  Are the presynaptic membrane particles the calcium channels?

Authors:  D W Pumplin; T S Reese; R Llinás
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

7.  Presynaptic currents in mouse motor endings.

Authors:  J L Brigant; A Mallart
Journal:  J Physiol       Date:  1982-12       Impact factor: 5.182

8.  Calcium-activated potassium channels in isolated presynaptic nerve terminals from rat brain.

Authors:  D K Bartschat; M P Blaustein
Journal:  J Physiol       Date:  1985-04       Impact factor: 5.182

9.  Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse.

Authors:  B Lang; J Newsom-Davis; C Prior; D Wray
Journal:  J Physiol       Date:  1983-11       Impact factor: 5.182

10.  Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones.

Authors:  H Fukunaga; A G Engel; B Lang; J Newsom-Davis; A Vincent
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

View more
  15 in total

1.  Reduction of calcium currents by Lambert-Eaton syndrome sera: motoneurons are preferentially affected, and L-type currents are spared.

Authors:  K D García; K G Beam
Journal:  J Neurosci       Date:  1996-08-15       Impact factor: 6.167

Review 2.  Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.

Authors:  Stephen D Meriney; Tyler B Tarr; Kristine S Ojala; Man Wu; Yizhi Li; David Lacomis; Adolfo Garcia-Ocaña; Mary Liang; Guillermo Valdomir; Peter Wipf
Journal:  Ann N Y Acad Sci       Date:  2017-11-10       Impact factor: 5.691

3.  Lambert-Eaton antibodies inhibit Ca2+ currents but paradoxically increase exocytosis during stimulus trains in bovine adrenal chromaffin cells.

Authors:  K L Engisch; M M Rich; N Cook; M C Nowycky
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

4.  Modelling the response to low-frequency repetitive nerve stimulation of myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Authors:  Francesc Miralles
Journal:  Med Biol Eng Comput       Date:  2016-03-25       Impact factor: 2.602

5.  Calcium channels link the muscle-derived synapse organizer laminin β2 to Bassoon and CAST/Erc2 to organize presynaptic active zones.

Authors:  Jie Chen; Sara E Billings; Hiroshi Nishimune
Journal:  J Neurosci       Date:  2011-01-12       Impact factor: 6.167

6.  Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions.

Authors:  F Giovannini; E Sher; R Webster; J Boot; B Lang
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

7.  Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.

Authors:  Michael T Flink; William D Atchison
Journal:  J Physiol       Date:  2002-09-01       Impact factor: 5.182

Review 8.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

9.  Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.

Authors:  Tyler B Tarr; David Lacomis; Stephen W Reddel; Mary Liang; Guillermo Valdomir; Michael Frasso; Peter Wipf; Stephen D Meriney
Journal:  J Physiol       Date:  2014-07-11       Impact factor: 5.182

10.  New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease.

Authors:  Man Wu; Hayley V White; Blake A Boehm; Christopher J Meriney; Kaylan Kerrigan; Michael Frasso; Mary Liang; Erika M Gotway; Madeleine R Wilcox; Jon W Johnson; Peter Wipf; Stephen D Meriney
Journal:  Neuropharmacology       Date:  2017-12-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.